Adagio Therapeutics (ADGI) – Momentum Movers
-
Adagio (ADGI) Climbs 27% After Announcing ADG20 Met Primary Endpoints Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19
-
Adagio Therapeutics (ADGI) Gains After Highlighting ADG20's Neutralizing Activity Against COVID Variants
-
-
-
Back to ADGI Stock Lookup